June 11, 2025 5:00pm

As a I had written “algos and electronic trading were thirsting” to profiteer

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering. What I do say is love ‘em and leave ‘em, we will need them …

Always be vigilant and in-the-know concerning your portfolio … why you need RMi!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Wednesday: RegMed Investors’ (RMi) pre-open: econs are “canning” markets and sector… https://www.regmedinvestors.com/articles/13954

Tuesday night’s RegMed Investors (RMi) Closing Bell: got it up… https://www.regmedinvestors.com/articles/13953

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed DOWN -1.10 points or -0.00%, the S&P closed DOWN -16.51 points or -0.27% while the Nasdaq closed DOWN -99.10 points or -0.50%

  • Indexes slumped Wednesday as trade talks continue …

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Inflation in May was lower than anticipated. The consumer price index rose 0.1% in May from April, less than the 0.2% estimate from economists. Core CPI, which strips out volatile food and energy prices, also increased 0.1%, less than expected.

Wednesday’s advance/decline line opened with a barely positive 16 incliner, 15 decline and 4 flats ending with a negative close of 10 incliners, 19 decliners and 6 flats    

Metrics:  Wednesday, the IBB was down -0.93%, the XBI was down -0.91% while the VIX was up +0.32 points or +1.89% at 17.27

 

Q2/25 – June – 1 neutral, 1 negative and 6 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • April – 11 positive and 10 negative closes

 

Wednesday Closing UP (6 of 6) +$ after Tuesday’s

  • Sangamo Therapeutics (SGMO +$0.0037),
  • Verve Therapeutics (VERV +$0.00 after Tuesday’s +$0.32 and Monday’s -$0.10),
  • Cellectis SA (CLLS +$0.0197),
  • Moderna (MRNA +$0.07 after Tuesday’s -$0.33 and Monday’s +$0.68),
  • Regenxbio (RGNX -$0.39),
  • Lenz Therapeutics (LENZ +$1.92 after Tuesday’s -$2.85 and Monday’s -0.74),

Flat (4):

  • bluebird bio (BLUE) P/E acquired
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Tuesday’s -$0.17 and Monday’s -$0.01
  • Homology Medicine (FIXX)
  • Ultragenyx Pharmaceuticals (RARE)

Wednesday’s Closing DOWN (10 of 25): 

  • Alnylam Pharmaceuticals (ALNY -$3.88 after Tuesday’s -$2.26 and Monday’s +$3.17),
  • Vericel (VCEL -$1.52 after Tuesday’s +$1.69 and Monday’s +$0.52),
  • CRISPR Therapeutics (CRSP -$1.42 after Tuesday’s +$0.79 and Monday’s +$0.23),
  • Mesoblast (MESO -$0.84 after Tuesday’s +$0.84),
  • Ionis Pharmaceuticals (IONS -$0.65),
  • AxoGen (AXGN -$0.50 after Tuesday’s +$0.20 and Monday’s -$0.51),
  • Solid Biosciences (SLDB -$0.22 after Tuesday’s +$0.1752 and Monday’s +$0.08)
  • Sage Therapeutics (SAGE -$0.21 after Tuesday’s +$0.20),
  • Agenus (AGEN -$0.20 after Tuesday’s -$0.21 and Monday’s -$0.40),
  • Adverum Biotechnologies (ADVM -$0.19 after Tuesday’s -$0.17 and Monday’s +$0.14),

 

The BOTTOM LINE: Wednesday's trading session ended with a negative territory, the Nasdaq leading slight losses by falling half a percent after May's Consumer Price Index (CPI) report saw inflation ease last month and President Trump announcing a trade deal with China.

  • On the one hand, you have what seem like encouraging headlines on the US and China moving towards a framework for a trade deal, but we don't have the actual trade deal as of yet.
  • This morning's CPI report showing that tariffs are not yet necessarily feeding their way through to inflation, at least not overly hot inflation. <Yahoo Finance>

The month evolves … Wednesday was a negative, Tuesday a barely positive followed by a neutral close of the cell and gene therapy sector …

  • The cell and gene therapy sector popped Friday after Thursday’s reverses on Thursday from a negative open with a barely positive close after Wednesday’s positive close – although slipping …
  • Following upsides on Tuesday and Monday) after its “napping and waking” in the May share pricing doldrums initiated by a sweetener of BPMC getting an acquired by BMY, MRNA regulatory approval and BNTX’s partnership with BMY.

As I also wrote, about June… Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

  • Although historically, June (in the past) has been a slow or weak month – I/we just saw a tremendous start (6/2) with partnership, acquisition and regulatory news 
  • Also, ASCO opens this month with probably a lot of news flow attracting attention of funds such as hedges and electronic traders.

There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

June ‘25: understand the “flow” …

  • 6/11 - Wednesday closed negative with 6 positive, 25 negative and 4 flats
  • 6/10 – Tuesday closed positive with 17 positive, 15 negative and 3 flats
  • 6/9 – Monday closed neutral with 16 positive, 16 negative and 3 flats
  • 6/6 – Friday closed positive with 28 positive, 4 negative and 3 flats
  • 6/5 – Thursday closed positive with 16 positive, 15 negative and 4 flats
  • 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
  • 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
  • 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Lenz Therapeutics (LENZ), Regenxbio (RGNX) and Moderna (MRNA)
  • Tuesday: Vericel (VCEL), Mesoblast (MESO) and CRISPR Therapeutics (CRSP)
  • Monday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Moderna (MRNA)

The worst three (3) in the session: 

  • Wednesday: Alnylam Pharmaceuticals (ALNY), Vericel (VCEL) and CRISPR Therapeutics (CRSP)
  • Tuesday: Lenz Therapeutics (LENZ), Alnylam Pharmaceuticals (ALNY) and uniQure NV (QURE)
  • Monday: Lenz Therapeutics (LENZ), AxoGen (AXGN) and Beam Therapeutics (BEAM)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.